Molotinib’s mechanism of action

Molotinib is a kinase inhibitor. Molotinib is specifically indicated for the treatment of adults with anemia in intermediate- or high-risk myelofibrosis (MF), including primary MF or secondary MF [polycythemia vera (PV) and essential thrombocythemia (ET)].

Molotinib is an inhibitor of wild-type Janus kinases 1 and 2 (JAK1/JAK2) and mutant JAK2V617F, which contribute to the signaling of many cytokines and growth factors important for hematopoiesis and immune function. Molotiniband its major human circulating metabolite M21 have higher inhibitory activity against JAK2 than JAK3 and tyrosine kinase 2 (TYK2). Molotinib and M21 also inhibits the type 1 activin A receptor (ACVR1), also known as activin receptor-like kinase 2 (ALK2), subsequently inhibiting hepatic hepcidin expression and increasing iron utilization, thereby increasing erythropoiesis. MF is a myeloproliferative neoplasm associated with constitutive activation and dysregulation of JAK signaling, leading to inflammation and overactivation of ACVR1. JAK signaling recruits and activates STAT (signal transducer and activator of transcription) proteins, resulting in nuclear localization and subsequent regulation of gene transcription.

It is worth mentioning that molotinib has demonstrated good efficacy and safety in clinical trials. In multiple studies, patients treated with molotinib have shown significant advantages in symptom improvement and improvement in laboratory indicators. For example, in one study, patients in the molotinib group had a significantly higher rate of reduction in total symptom scores than those in the control group, fully demonstrating the drug's ability to improve patients' symptoms.

In summary, molotinib intervenes in the core pathological mechanism of myelofibrosis by inhibiting the activities of JAK1/JAK2 and ACVR1 in a two-pronged approach. This precise treatment strategy not only helps control the progression of the disease, but also significantly improves patients' symptoms and quality of life, bringing new treatment hope to patients with myelofibrosis.